Viatris Inc. is a global pharmaceutical company established in 2020 following the merger of Mylan N.V. and Pfizer's off-patent medicine division, Upjohn. The company operates a diversified business model spanning the entire lifecycle of medications, from established brands to complex generics and specialty pharmaceuticals. Viatris's extensive product portfolio includes well-known legacy brands such as Lipitor, Viagra, Lyrica, and Norvasc, which continue to generate significant cash flow, particularly in emerging markets. In addition to its branded products, Viatris is a major player in the global generic drug market, leveraging a massive manufacturing and supply chain infrastructure that reaches over 165 countries and territories. The company's revenue is geographically diversified across developed markets (North America and Europe), emerging markets, and the JANZ (Japan, Australia, New Zealand) region. Recently, Viatris has transitioned into a strategic growth period focused on high-margin, high-barrier-to-entry specialty therapeutic areas such as ophthalmology and complex injectables, bolstered by acquisitions like Oyster Point Pharma and Famy Life Sciences. By divesting non-core assets and paying down debt incurred from its formation, Viatris aims to position itself as a leaner, specialty-focused healthcare leader.
